| scholarly article | Q13442814 |
| P2093 | author name string | P Johansen | |
| N Graf | |||
| G Senti | |||
| S von Moos | |||
| T M Kündig | |||
| F Tay | |||
| P2860 | cites work | Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis | Q79189373 |
| Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines. | Q34593082 | ||
| Sublingual immunotherapy: a comprehensive review. | Q36468537 | ||
| Advances in transcutaneous vaccine delivery: Do all ways lead to Rome? | Q37792508 | ||
| 100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). | Q37841682 | ||
| Recombinant allergens: what does the future hold? | Q37860548 | ||
| Antigen presentation by Langerhans cells | Q38067945 | ||
| The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy | Q40294402 | ||
| Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study | Q40309560 | ||
| Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. | Q44574133 | ||
| Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. | Q51719532 | ||
| Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. | Q51811667 | ||
| Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. | Q53424714 | ||
| Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies | Q60312277 | ||
| Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy | Q60473182 | ||
| P433 | issue | 6 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 707-710 | |
| P577 | publication date | 2015-03-13 | |
| P1433 | published in | Allergy | Q2699825 |
| P1476 | title | Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials | |
| P478 | volume | 70 |
| Q30248317 | Allergen-specific immunotherapy: is it vaccination against toxins after all? |
| Q88289109 | Dust mite allergen-specific immunotherapy increases IL4 DNA methylation and induces Der p-specific T cell tolerance in children with allergic asthma |
| Q38687640 | Emerging drugs for the treatment of perennial allergic rhinitis |
| Q38638657 | Epicutaneous immunotherapy for food allergy as a novel pathway for oral tolerance induction |
| Q59807678 | Epicutaneous immunotherapy in rhino-conjunctivitis and food allergies: a review of the literature |
| Q37561165 | Heat-labile Escherichia coli toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination. |
| Q38973411 | IgE-associated allergic disorders: recent advances in etiology, diagnosis, and treatment |
| Q49025332 | International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis |
| Q36033148 | Laser-facilitated epicutaneous immunotherapy to IgE-mediated allergy |
| Q38600884 | Latest developments in allergic rhinitis in Allergy for clinicians and researchers |
| Q90694778 | Loricrin: Past, Present, and Future |
| Q39378515 | Molecular aspects of allergens in atopic dermatitis |
| Q47884083 | Next generation immunotherapy for tree pollen allergies |
| Q38857421 | Novel strategies for the treatment of grass pollen-induced allergic rhinitis |
| Q55380934 | Novel strategies in immunotherapy for allergic diseases. |
| Q36056484 | Potential of nanoparticles for allergen-specific immunotherapy - use of silica nanoparticles as vaccination platform |
| Q45072722 | Synchronous Immune Alterations Mirror Clinical Response During Allergen Immunotherapy. |
| Q26771289 | The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy |
| Q53505747 | [Innovative forms of specific immunotherapy]. |
Search more.